ExpreS2ion will participate in key investor events in December 2021
Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.
To participate, please register or find more information via the links below. Additional information and updates can be found on the Meet Us page of the ExpreS2ion website.
Aktiespararna’s Stora Aktiedagen
When: 9:00 CET on December 2nd
Where: Hotel Birger Jarl in Stockholm, Sweden and on Aktiespararna’s YouTube channel
Join CEO Bent Frandsen for a live update at Aktiespararna’s Stora Aktiedagen in Stockholm. Additional information and registration can are found on the event website.
HC Andersen Capital and Nordea Markets’ Virtual Growth Days Seminar
When: 11:00 CET on December 9th
Where: Virtual webcast
Nordea Markets, Corporates & Institutions and HC Andersen Capital hold a virtual seminar focusing on Nordic growth companies for both institutional and private investors. Join CEO Bent Frandsen for a presentation and Q&A session. More information and registration can be found on HC Andersen Capital’s website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel capsid VLP based vaccines through its 34% owned joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com.